Zevra Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ZVRA Nasdaq 2830 www.zevra.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zevra Therapeutics, Inc.

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - Aug 25th, 2026 5:30 am
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Aug 21st, 2026 2:30 pm
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review? - Aug 6th, 2026 11:12 pm
Zevra Therapeutics Q2 Earnings Call Highlights - Aug 6th, 2026 2:04 am
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ... - Aug 5th, 2026 11:08 pm
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates - Aug 5th, 2026 6:35 pm
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update - Aug 5th, 2026 2:05 pm
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference - Aug 4th, 2026 5:30 am
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) - Aug 3rd, 2026 5:30 am
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’ - Jul 24th, 2026 12:43 pm
Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application - Jul 24th, 2026 8:38 am
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off? - Jul 24th, 2026 6:48 am
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union - Jul 24th, 2026 5:30 am
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call - Jul 22nd, 2026 5:30 am
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) - Jun 23rd, 2026 5:30 am
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - Jun 11th, 2026 6:30 am
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? - Jun 9th, 2026 3:19 pm
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Jun 9th, 2026 10:50 am
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug - Jun 8th, 2026 12:19 pm
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041 - Jun 8th, 2026 10:25 am